Korea Research Institute of Chemical Technology

Other

Korea Institute of Science and Technology

The Catholic University of Korea Industry-academic Cooperation Foundation

Samsung Life Public Welfare Foundation

Dae Young Jeong

Jae Yang Kong

Heeyeong Cho

Ae Nim Pae

Kyung Il Choi

Yong Seo Cho

Hun Yeong Koh

Soon Bang Kang

Hee-Yoon Lee

Youseung Kim

Min Seok Jang

Hyeon Young Kim

Gyochang Keum

Ji Young Jung

Chong Ock Lee

Do Hyun Nam

Woo Kyu Park

Hee-Jong Lim

Young-Dae Gong

Gildon Choi

Mi Young Cha

Ge Hyeong Lee

Kyung Ho Kang

Moon-Kook Jeon

Taeho Lee

Sun Ho Jung

Ji Hye Choi

Soon-Hee Hwang

Wan Uk Kim

Su Jung Park

Taeg-Su Jang

Chul Soo Cho

Sae-Bom Yoon

Heung Kyoung Lee

Victor Sukbong Hong

Eun Jin Han

Sunkyung Lee

Ho Jun Seol

The present invention relates to a pharmaceutical composition for preventing or treating autoimmune diseases or tumors, containing, as an active ingredient, a tricyclic compound represented by the following Chemical Formula 1 or a pharmaceutically acceptable salt thereof, and a health food composition for preventing or alleviating autoimmune diseases or tumors, containing the tricyclic compound as an active ingredient,

Tricyclic compound as IRAK4 inhibitor

The preset invention relates to a novel 8-oxoprotoberberine derivative or a pharmaceutically acceptable salt thereof, a preparation method thereof, and a pharmaceutical composition for preventing or treating diseases associated with the activity of NFAT5 containing the same as an active ingredient. The novel 8-oxoproteoberberine derivative or the pharmaceutically acceptable salt thereof according to the present invention can be useful in a pharmaceutical composition for preventing or treating diseases associated with the activity of NFAT5, particularly rheumatoid arthritis or inflammatory diseases, since it is ascertained that the derivative or a pharmaceutically acceptable salt thereof has remarkably increased oral absorption compared with known protoberberine due to an improvement in the properties thereof, and inhibits the activity of NFAT5 and the secretion of inflammatory cytokines and reduces the expression of NAFT5 in mice with rheumatoid arthritis by directly inhibiting the transcription of NFT5.

8-oxoprotoberberine derivative or pharmaceutically acceptable salt thereof, preparation method therefor and pharmaceutical composition for preventing or treating diseases associated with activity of NFAT5, containing same as active ingredient

Disclosed herein are 2,4-disubstituted-5-aminocarbonyl-1,3-thiazole derivatives, a preparation method thereof, and a therapeutic agent for treating inflammatory diseases induced by SPC, which contains the derivative as an active ingredient. The anti-inflammatory effect of the 2,4-disubstituted-5-aminocarbonyl-1,3-thiazole derivatives was analyzed through a test employing human dermal cells and an animal test using mice and, as a result, it was found that the derivatives showed excellent inhibitory activity on SPC receptor compared to thiazole derivatives known in the prior art. Thus, the 2,4-disubstituted-5-aminocarbonyl-1,3-thiazole derivatives or pharmaceutically acceptable salts thereof are useful as active ingredients in therapeutic agents for treating inflammatory diseases, such as inflammation, pruritus and skin infection, which appear in atopic dermatitis and other diseases induced by SPC activity. wherein R, R, Rand Rare as defined in the specification.

2,4-disubstituted-5-aminocarbonyl-1,3-thiazole derivatives for therapeutic agent of antiinflammatory disease, method thereof for preparation, therapeutic agent for antiinflammatory disease induced by SPC activity containing the same

Pyrrolidinone derivatives, their preparation and pharmaceutical composition comprising the same

Isoxazolylalkylpiperazine derivatives having selective biological activity at dopamine D3 or D4 receptor, and preparation thereof

Tetrahydropyridine derivatives acting on muscarinic acetylcholine receptors

4,5,-dihydroisoxazolylakylpiperazine derivatives having selective biological activity at dopamine D3 or D4 receptor, and preparation thereof

Growing community of inventors

Daejeon, South Korea

Dae Young Jeong